Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
550.6 INR | -0.02% | +2.96% | +66.77% |
Apr. 18 | Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US | MT |
Apr. 17 | Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit | MT |
Sales 2022 | 11.47B 137M | Sales 2023 | 10.52B 126M | Capitalization | 19.91B 239M |
---|---|---|---|---|---|
Net income 2022 | 607M 7.27M | Net income 2023 | -325M -3.89M | EV / Sales 2022 | 3.58 x |
Net Debt 2022 | 6.58B 78.84M | Net Debt 2023 | 7.79B 93.35M | EV / Sales 2023 | 2.63 x |
P/E ratio 2022 |
54.7
x | P/E ratio 2023 |
-61.3
x | Employees | 1,179 |
Yield 2022 |
0.28% | Yield 2023 |
-
| Free-Float | 39.28% |
Latest transcript on Shilpa Medicare Limited
1 day | +0.05% | ||
1 week | +2.96% | ||
Current month | +19.43% | ||
1 month | +11.37% | ||
3 months | +73.54% | ||
6 months | +58.22% | ||
Current year | +66.77% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 87-11-19 | |
Alpesh Dalal
DFI | Director of Finance/CFO | - | 21-05-30 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 87-11-19 | |
Director/Board Member | 58 | 21-09-01 | |
Arvind Vasudeva
BRD | Director/Board Member | 63 | 21-09-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 117 M€ | -0.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 550.6 | -0.02% | 18 424 |
24-04-30 | 550.7 | +2.75% | 37,091 |
24-04-29 | 536 | -1.75% | 38,100 |
24-04-26 | 545.5 | +2.86% | 27,032 |
24-04-25 | 530.4 | -0.15% | 20,984 |
Delayed Quote Bombay S.E., May 02, 2024 at 03:02 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+66.77% | 573M | |
+33.25% | 699B | |
+28.59% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.81% | 236B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- SHILPAMED Stock